Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
ACS Chem Biol
2010 Dec 17;512:1183-91. doi: 10.1021/cb1002366.
Show Gene links
Show Anatomy links
Symptomatic relief of botulinum neurotoxin/a intoxication with aminopyridines: a new twist on an old molecule.
Mayorov AV
,
Willis B
,
Di Mola A
,
Adler D
,
Borgia J
,
Jackson O
,
Wang J
,
Luo Y
,
Tang L
,
Knapp RJ
,
Natarajan C
,
Goodnough MC
,
Zilberberg N
,
Simpson LL
,
Janda KD
.
???displayArticle.abstract???
Botulinum neurotoxins (BoNT) are the etiological agents responsible for botulism, a disease characterized by peripheral neuromuscular blockade and a characteristic flaccid paralysis of humans. BoNT/A is the most toxic protein known to man and has been classified by the Centers of Disease Control (CDC) as one of the six highest-risk threat agents for bioterrorism. Of particular concern is the apparent lack of clinical interventions that can reverse cellular intoxication. Efforts to uncover molecules that can act within an intoxicated cell so as to provide symptomatic relief to BoNT/A are paramount. Aminopyridines have shown clinical efficacy for multiple sclerosis treatment as well as BoNT/A intoxication; yet, aminopyridines for BoNT/A treatment has been abandoned because of bloodbrain barrier (BBB) penetration producing undesired neurotoxic side effects. Two aminopyridines (5 and 11) exhibited inhibitory activity toward Shaker-IR voltage-gated potassium (K(V)1.x) channels with potencies similar to that of the previous "gold-standard", 3,4-diaminopyridine (3,4-DAP), including reversal of symptoms from BoNT-induced paralysis in phrenic nerve-hemidiaphragm preparations. Importantly, pharmacokinetic experiments revealed a lack of BBB penetration of 5, which is a significant advancement toward resolving the neurotoxicity issues associated with prolonged 3,4-DAP treatments. Finally, 5 was found to be as effective as 3,4-DAP in rescuing BoNT-poisoned mice in the mouse lethality assay, signifying an optimized balance between the undesired permeability across the BBB and the required permeability across lipid cellular membranes. The results demonstrate that 5 is the most promising small molecule K(+) channel inhibitor discovered to date for the treatment of BoNT/A intoxication.
Adler,
Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations.
1995, Pubmed
Adler,
Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations.
1995,
Pubmed
Arnon,
Botulinum toxin as a biological weapon: medical and public health management.
2001,
Pubmed
Bever,
Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis.
1990,
Pubmed
Caballero,
Molecular docking study of the binding of aminopyridines within the K+ channel.
2007,
Pubmed
Carlsson,
Can 4-aminopyridine be used to reverse anaesthesia and muscle relaxation?
1983,
Pubmed
Choquet,
Mechanism of 4-aminopyridine action on voltage-gated potassium channels in lymphocytes.
1992,
Pubmed
Claydon,
4-aminopyridine prevents the conformational changes associated with p/c-type inactivation in shaker channels.
2007,
Pubmed
,
Xenbase
Damsma,
Differential effects of 4-aminopyridine and 2,4-diaminopyridine on the in vivo release of acetylcholine and dopamine in freely moving rats measured by intrastriatal dialysis.
1988,
Pubmed
Davidson,
4-Aminopyridine in the treatment of Alzheimer's disease.
1988,
Pubmed
Davis,
Human type A botulism and treatment with 3,4-diaminopyridine.
1992,
Pubmed
Dickerson,
The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication.
2006,
Pubmed
Dock,
[Treatment of severe botulism with 3,4-diaminopyridine]].
2002,
Pubmed
Eubanks,
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.
2007,
Pubmed
Johnson,
Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective.
2001,
Pubmed
Judge,
Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.
2006,
Pubmed
Kolb,
The growing impact of click chemistry on drug discovery.
2003,
Pubmed
Kozminsky-Atias,
Isolation of the first toxin from the scorpion Buthus occitanus israelis showing preference for Shaker potassium channels.
2007,
Pubmed
,
Xenbase
Lippiat,
A residue in the intracellular vestibule of the pore is critical for gating and permeation in Ca2+-activated K+ (BKCa) channels.
2000,
Pubmed
López-Barneo,
Effects of external cations and mutations in the pore region on C-type inactivation of Shaker potassium channels.
1993,
Pubmed
,
Xenbase
Lundh,
Antagonism of the paralysis produced by botulinum toxin in the rat. The effects of tetraethylammonium, guanidine and 4-aminopyridine.
1977,
Pubmed
Lundh,
Restoration of transmitter release in botulinum-poisoned skeletal muscle.
1976,
Pubmed
McEvoy,
3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
1989,
Pubmed
Metezeau,
Botulinum toxin type A: kinetics of calcium dependent paralysis of the neuromuscular junction and antagonism by drugs and animal toxins.
1982,
Pubmed
Muñoz-Caro,
The nature of the receptor site for the reversible K+ channel blocking by aminopyridines.
2002,
Pubmed
Niño,
Theoretical analysis of the molecular determinants responsible for the K(+) channel blocking by aminopyridines.
2001,
Pubmed
Niño,
Rational modelling of the voltage-dependent K+ channel inactivation by aminopyridines.
2003,
Pubmed
Osborne,
The Janus faces of botulinum neurotoxin: sensational medicine and deadly biological weapon.
2007,
Pubmed
Plewa,
Hemodynamic effects of 3,4-diaminopyridine in a swine model of verapamil toxicity.
1994,
Pubmed
Schantz,
Properties and use of botulinum toxin and other microbial neurotoxins in medicine.
1992,
Pubmed
Schwid,
Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.
1997,
Pubmed
Simpson,
Identification of the major steps in botulinum toxin action.
2004,
Pubmed
Simpson,
Studies on the binding of botulinum toxin type A to the rat phrenic nerve-hemidiaphragm preparation.
1974,
Pubmed
Simpson,
Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction.
1980,
Pubmed
Singh,
Intimate details of the most poisonous poison.
2000,
Pubmed
Singh,
Development of more potent 4-dimethylaminopyridine analogues.
2007,
Pubmed
Uchiyama,
Equipotency of anti-curare activity of 4-aminopyridine and 3,4-diaminopyridine in anesthetized rats.
1985,
Pubmed
VOHRA,
SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF SOME AMINOPYRIDINES, IMIDAZOPYRIDINES, AND TRIAZOLOPYRIDINES.
1965,
Pubmed
Willis,
The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison.
2008,
Pubmed
